International journal of gynaecology and obstetrics : the official organ of the International Federation of Gynaecology and Obstetrics
-
Int J Gynaecol Obstet · Aug 2003
Review Meta AnalysisMisoprostol use during the third stage of labor.
To systematically review the efficacy of misoprostol compared with placebo or other uterotonics in preventing maternal morbidity associated with the third stage of labor. ⋯ Misoprostol was inferior to oxytocin and other uterotonics with regard to any of the third stage of labor outcomes assessed. However, when compared to placebo, misoprostol had a decreased risk of needing additional uterotonics. Thus, in less-developed countries where administration of parenteral uterotonic drugs may be problematic, misoprostol represents a reasonable agent for the management of the third stage of labor. Additional randomized clinical trials examining objective outcome measures (i.e. need for blood transfusion or 10% hemoglobin change) may further define benefits and risks of misoprostol use during the third stage of labor.
-
Int J Gynaecol Obstet · Jul 2003
Randomized Controlled Trial Comparative Study Clinical TrialPethidine versus tramadol for pain relief during labor.
To evaluate and compare the analgesic efficacy and adverse effects of tramadol and pethidine in labor. ⋯ Pethidine seems to be a better alternative than tramadol in obstetric analgesia because of its superiority in analgesic efficacy and low incidence of maternal side effects.
-
Int J Gynaecol Obstet · Jul 2003
Randomized Controlled Trial Comparative Study Clinical TrialOral misoprostol vs. intravenous oxytocin for labor induction in women with prelabor rupture of membranes at term.
-
Int J Gynaecol Obstet · Jun 2003
Location of the appendix in the gravid patient: a re-evaluation of the established concept.
To determine the anatomical location of the appendix, as it may change during pregnancy. ⋯ Our study did not show that pregnancy changes the location of the appendix.
-
Emergency obstetric care (EmOC), like any health intervention, requires resources, and resources are almost always limited. This forces decision makers to take into account the costs (and effectiveness) of EmOC provision and compare them with the costs (and effectiveness) of other health interventions. ⋯ A definition of EmOC provision cost is offered and then explained by progressively refining a simple measure of expenditures on all that is used to provide EmOC services. Thereupon the process of collecting cost data and calculating costs is outlined using a simple spreadsheet format, and issues related to the analysis of costs and cost-effectiveness are discussed.